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Background: Over the past 20 years, the cardiac and total mortality in the placebo arm of heart failure (HF) trials has decreased by almost 70% 
with ACE inhibitors (ACE-I), beta blockers and aldosterone inhibitors becoming the cornerstone of pharmacologic management. In this study, we 
sought to determine if the improvement in survival can be explained by the addition of these, and other medications, for HF treatment.
Methods: We searched for published double-blind, placebo-controlled clinical trials which evaluated drugs to decrease mortality in HF. This 
analysis included trials with at least 200 subjects, minimum follow-up of at least 6 month, and reported all-cause and cardiovascular (CV) mortality. 
A separate meta-analysis was performed for each drug class for both total and CV mortality reduction. This included ACE-I (n=6), Beta Blockers 
(n=14), angiotensin receptor inhibitor (ARB) (N=8), digoxin (N=1), and aldosterone inhibitor (n=1). We then combined the results to determine the 
expected mortality benefit from optimal treatment.
Results: The CV and all-cause mortality reduction with ACE-I were 20.3% and 19.0% respectively, while Beta Blockers had a decrease in mortality 
of 25.5% and 24.5% respectively. There is no additional mortality benefit from the addition of ARB or digoxin. While aldosterone blockade has been 
demonstrated to decrease mortality by 38%, only a third of patients in recent trials were on these agents. According to this analysis, the addition 
of ACE-I, beta blockers, and aldosterone inhibition produces only a 46% CV and a 43% all-cause mortality reduction in HF, not the 70% and 63% 
respective reduction seen in the clinical trials.
Conclusions: There is a significant CV and all-cause mortality reduction for HF patients over the past 20 years that can not be fully be explained 
by addition of our standard therapies of ACE-I and Beta Blocker. These results suggest that other effects of being included in clinical trials, including 
cessation of agents that worsen mortality, such as antiarrhythmics and calcium channel blockers, early adoption of adjunctive device therapy or a 
significant Hawthorne effect may also be contributing to the marked reduction in mortality seen in HF trials.
